Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1122558

registered interest
date	11/04/2019
answering body	Cabinet Office
answering dept id	53
answering dept short name	Cabinet Office
answering dept sort name	Cabinet Office
hansard heading	Civil Servants: Location
house id	1
legislature	25259 pref label House of Commons
question text	What steps are his department taking to move civil service jobs out of London in line with the Government’s industrial strategy.
tabling member constituency	Southampton, Itchen
tabling member printed	Royston Smith
uin	910478
answer	answer is ministerial correction date of answer 24/04/2019 answer text <p>Our Places for Growth programme will relocate Civil Servants out of London, with at least 1,000 roles moved by 2022 and thousands more by 2030.</p><p> </p><p>This in addition to the twelve new public bodies that will be located outside of London.</p> answering member constituency Hertsmere answering member printed Oliver Dowden question first answered 24/04/2019 15:41:57 answering member 4441 label Biography information for Oliver Dowden
tabling member	4478 label Biography information for Royston Smith

1110380

registered interest
date	08/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescriptions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what his Department's policy is to ensure that people who require repeat prescriptions are able to have access to the medicine they require.
tabling member constituency	Southampton, Itchen
tabling member printed	Royston Smith
uin	242193
answer	answer is ministerial correction date of answer 12/04/2019 answer text <p>The Government does not distinguish between acute and repeat prescriptions. Over two million prescription items – acute and repeat - are dispensed in England alone every day. Medicine supply problems can occur for a wide variety of reasons, and the Department has well established routine procedures to deal with shortages, from whatever cause, working closely with manufacturers, the National Health Service and patient groups.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 12/04/2019 14:15:30 answering member 4455 label Biography information for Seema Kennedy
tabling member	4478 label Biography information for Royston Smith

1110381

registered interest
date	08/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescriptions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many people are registered for repeat prescriptions.
tabling member constituency	Southampton, Itchen
tabling member printed	Royston Smith
uin	242194
answer	answer is ministerial correction date of answer 11/04/2019 answer text <p>Whether a prescription is a repeat or not is not indicated on the prescription therefore it is not recorded centrally.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/04/2019 16:59:25 answering member 4455 label Biography information for Seema Kennedy
tabling member	4478 label Biography information for Royston Smith

1110385

registered interest
date	08/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescriptions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the cost to the public purse has been of free repeat prescriptions in each of the last three years.
tabling member constituency	Southampton, Itchen
tabling member printed	Royston Smith
uin	242195
answer	answer is ministerial correction date of answer 12/04/2019 answer text <p>Whether a prescription is a repeat or not is not indicated on the prescription. Therefore, the cost to the public purse of free repeat prescriptions is not recorded centrally. However, we know, for the past three years, that around almost 90% of prescriptions are dispensed free of charge.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 12/04/2019 14:14:47 answering member 4455 label Biography information for Seema Kennedy
tabling member	4478 label Biography information for Royston Smith

1108993

registered interest
date	02/04/2019
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Department for Transport: Written Questions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Transport, when he plans to respond to Question 210578 on Cycling: Safety tabled on 21 January 2019 by the hon. Member for Southampton Itchen.
tabling member constituency	Southampton, Itchen
tabling member printed	Royston Smith
uin	240040
answer	answer is ministerial correction date of answer 04/04/2019 answer text <p>I apologise that due to an administrative error, this question was not answered. This has now been rectified.</p><p> </p> answering member constituency Hereford and South Herefordshire answering member printed Jesse Norman question first answered 04/04/2019 11:25:37 answering member 3991 label Biography information for Jesse Norman
tabling member	4478 label Biography information for Royston Smith

1078455

registered interest
date	27/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Naproxen
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the availability of naproxen on the NHS.
tabling member constituency	Southampton, Itchen
tabling member printed	Royston Smith
uin	226707
answer	answer is ministerial correction date of answer 06/03/2019 answer text <p>The Department is aware that supplies of naproxen tablets were limited during January and early February due to a manufacturing issue with the active pharmaceutical ingredient. During this time, we worked closely with all suppliers of naproxen tablets to expedite further deliveries.</p><p>Supplies of naproxen tablets are currently available in volumes sufficient to meet national requirements. We will continue to work closely with all manufacturers of naproxen tablets to monitor the overall supply situation to ensure supplies continue to remain available. We have provided updates about the naproxen supply situation to the National Health Service via primary and secondary care networks and will continue to do this.</p><p>We understand that naproxen, and other medicines, are vitally important to many people in this country. Our contingency plans include sensible mitigations for medicines that come to the United Kingdom from or via the European Union to ensure that the supply of medicines for patients is not disrupted.</p><p>The Department is unable to discuss the specific arrangements for naproxen, because to reassure companies engaging in our contingency plans, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department’s programme.</p><p>A comprehensive plan has been put in place in the form of a multi-layered approach to minimise any supply disruption:</p><p>- securing, via the Department for Transport, additional roll on roll off freight capacity (away from the short straits) for goods to continue to come into the UK from 29 March;</p><p>- buffer stocks and stockpiling (where this is practical) or asking industry to build up buffer stocks in the UK before 29 March;</p><p>- buying extra warehouse space for the additional stock to be held in;</p><p>- supporting companies in booking space on aircraft for products which require an immediate shipment due to short shelf-life or specific storage conditions;</p><p>- making changes to, or clarifications of, certain regulatory requirements so that companies can continue to sell their products in the UK even if we have ‘no deal’; and</p><p>- strengthening the processes and resources used to deal with shortages in the event that they do occur.</p><p>No one of these measures will work on its own. A combination of securing freight, buffer stocks, stockpiling and warehousing, regulatory flexibility, and clinical assessment and decision making, will be required help to ensure the continuation of medical supplies.</p><p>Throughout enacting our plans, the response from pharmaceutical companies has been hugely positive. Companies share our aims of ensuring continuity of medicines’ supply for patients is maintained and able to cope with any potential delays at the border that may arise in the event the UK leaves the EU without a deal.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 226170 226171 226708 question first answered 06/03/2019 11:02:14 answering member 1585 label Biography information for Stephen Hammond
tabling member	4478 label Biography information for Royston Smith

1078456

registered interest
date	27/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Naproxen
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of stocks of naproxen held by the NHS in the event that the UK leaves the EU.
tabling member constituency	Southampton, Itchen
tabling member printed	Royston Smith
uin	226708
answer	answer is ministerial correction date of answer 06/03/2019 answer text <p>The Department is aware that supplies of naproxen tablets were limited during January and early February due to a manufacturing issue with the active pharmaceutical ingredient. During this time, we worked closely with all suppliers of naproxen tablets to expedite further deliveries.</p><p>Supplies of naproxen tablets are currently available in volumes sufficient to meet national requirements. We will continue to work closely with all manufacturers of naproxen tablets to monitor the overall supply situation to ensure supplies continue to remain available. We have provided updates about the naproxen supply situation to the National Health Service via primary and secondary care networks and will continue to do this.</p><p>We understand that naproxen, and other medicines, are vitally important to many people in this country. Our contingency plans include sensible mitigations for medicines that come to the United Kingdom from or via the European Union to ensure that the supply of medicines for patients is not disrupted.</p><p>The Department is unable to discuss the specific arrangements for naproxen, because to reassure companies engaging in our contingency plans, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department’s programme.</p><p>A comprehensive plan has been put in place in the form of a multi-layered approach to minimise any supply disruption:</p><p>- securing, via the Department for Transport, additional roll on roll off freight capacity (away from the short straits) for goods to continue to come into the UK from 29 March;</p><p>- buffer stocks and stockpiling (where this is practical) or asking industry to build up buffer stocks in the UK before 29 March;</p><p>- buying extra warehouse space for the additional stock to be held in;</p><p>- supporting companies in booking space on aircraft for products which require an immediate shipment due to short shelf-life or specific storage conditions;</p><p>- making changes to, or clarifications of, certain regulatory requirements so that companies can continue to sell their products in the UK even if we have ‘no deal’; and</p><p>- strengthening the processes and resources used to deal with shortages in the event that they do occur.</p><p>No one of these measures will work on its own. A combination of securing freight, buffer stocks, stockpiling and warehousing, regulatory flexibility, and clinical assessment and decision making, will be required help to ensure the continuation of medical supplies.</p><p>Throughout enacting our plans, the response from pharmaceutical companies has been hugely positive. Companies share our aims of ensuring continuity of medicines’ supply for patients is maintained and able to cope with any potential delays at the border that may arise in the event the UK leaves the EU without a deal.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 226170 226171 226707 question first answered 06/03/2019 11:02:14 answering member 1585 label Biography information for Stephen Hammond
tabling member	4478 label Biography information for Royston Smith

1077606

registered interest
date	26/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Naproxen
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 9 January 2019 to Question 205406 on Naproxen, what progress has been made on securing additional deliveries of naproxen.
tabling member constituency	Southampton, Itchen
tabling member printed	Royston Smith
uin	226170
answer	answer is ministerial correction date of answer 06/03/2019 answer text <p>The Department is aware that supplies of naproxen tablets were limited during January and early February due to a manufacturing issue with the active pharmaceutical ingredient. During this time, we worked closely with all suppliers of naproxen tablets to expedite further deliveries.</p><p>Supplies of naproxen tablets are currently available in volumes sufficient to meet national requirements. We will continue to work closely with all manufacturers of naproxen tablets to monitor the overall supply situation to ensure supplies continue to remain available. We have provided updates about the naproxen supply situation to the National Health Service via primary and secondary care networks and will continue to do this.</p><p>We understand that naproxen, and other medicines, are vitally important to many people in this country. Our contingency plans include sensible mitigations for medicines that come to the United Kingdom from or via the European Union to ensure that the supply of medicines for patients is not disrupted.</p><p>The Department is unable to discuss the specific arrangements for naproxen, because to reassure companies engaging in our contingency plans, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department’s programme.</p><p>A comprehensive plan has been put in place in the form of a multi-layered approach to minimise any supply disruption:</p><p>- securing, via the Department for Transport, additional roll on roll off freight capacity (away from the short straits) for goods to continue to come into the UK from 29 March;</p><p>- buffer stocks and stockpiling (where this is practical) or asking industry to build up buffer stocks in the UK before 29 March;</p><p>- buying extra warehouse space for the additional stock to be held in;</p><p>- supporting companies in booking space on aircraft for products which require an immediate shipment due to short shelf-life or specific storage conditions;</p><p>- making changes to, or clarifications of, certain regulatory requirements so that companies can continue to sell their products in the UK even if we have ‘no deal’; and</p><p>- strengthening the processes and resources used to deal with shortages in the event that they do occur.</p><p>No one of these measures will work on its own. A combination of securing freight, buffer stocks, stockpiling and warehousing, regulatory flexibility, and clinical assessment and decision making, will be required help to ensure the continuation of medical supplies.</p><p>Throughout enacting our plans, the response from pharmaceutical companies has been hugely positive. Companies share our aims of ensuring continuity of medicines’ supply for patients is maintained and able to cope with any potential delays at the border that may arise in the event the UK leaves the EU without a deal.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 226171 226707 226708 question first answered 06/03/2019 11:02:14 answering member 1585 label Biography information for Stephen Hammond
tabling member	4478 label Biography information for Royston Smith

1077615

registered interest
date	26/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Naproxen
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 16 January 2019 to Question 209362, what further discussions his Department has had with the health sector on the supply of Naproxen.
tabling member constituency	Southampton, Itchen
tabling member printed	Royston Smith
uin	226171
answer	answer is ministerial correction date of answer 06/03/2019 answer text <p>The Department is aware that supplies of naproxen tablets were limited during January and early February due to a manufacturing issue with the active pharmaceutical ingredient. During this time, we worked closely with all suppliers of naproxen tablets to expedite further deliveries.</p><p>Supplies of naproxen tablets are currently available in volumes sufficient to meet national requirements. We will continue to work closely with all manufacturers of naproxen tablets to monitor the overall supply situation to ensure supplies continue to remain available. We have provided updates about the naproxen supply situation to the National Health Service via primary and secondary care networks and will continue to do this.</p><p>We understand that naproxen, and other medicines, are vitally important to many people in this country. Our contingency plans include sensible mitigations for medicines that come to the United Kingdom from or via the European Union to ensure that the supply of medicines for patients is not disrupted.</p><p>The Department is unable to discuss the specific arrangements for naproxen, because to reassure companies engaging in our contingency plans, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department’s programme.</p><p>A comprehensive plan has been put in place in the form of a multi-layered approach to minimise any supply disruption:</p><p>- securing, via the Department for Transport, additional roll on roll off freight capacity (away from the short straits) for goods to continue to come into the UK from 29 March;</p><p>- buffer stocks and stockpiling (where this is practical) or asking industry to build up buffer stocks in the UK before 29 March;</p><p>- buying extra warehouse space for the additional stock to be held in;</p><p>- supporting companies in booking space on aircraft for products which require an immediate shipment due to short shelf-life or specific storage conditions;</p><p>- making changes to, or clarifications of, certain regulatory requirements so that companies can continue to sell their products in the UK even if we have ‘no deal’; and</p><p>- strengthening the processes and resources used to deal with shortages in the event that they do occur.</p><p>No one of these measures will work on its own. A combination of securing freight, buffer stocks, stockpiling and warehousing, regulatory flexibility, and clinical assessment and decision making, will be required help to ensure the continuation of medical supplies.</p><p>Throughout enacting our plans, the response from pharmaceutical companies has been hugely positive. Companies share our aims of ensuring continuity of medicines’ supply for patients is maintained and able to cope with any potential delays at the border that may arise in the event the UK leaves the EU without a deal.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 226170 226707 226708 question first answered 06/03/2019 11:02:14 answering member 1585 label Biography information for Stephen Hammond
tabling member	4478 label Biography information for Royston Smith

1064691

registered interest
date	21/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lung Diseases: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the NHS Long Term Plan, what the timeframe is for the introduction of lung health checks in Southampton Care Commissioning Group.
tabling member constituency	Southampton, Itchen
tabling member printed	Royston Smith
uin	224354
answer	answer is ministerial correction date of answer 28/02/2019 answer text <p>Local areas are beginning to work up plans for the implementation of lung health checks in their area, and funding has been made available to enable projects to start in 2019-20. Total costs are just under £70 million and will pay for nurses, radiographers and radiologists to provide lung health check appointments and low dose computed tomography (CT) scans.</p><p> </p><p>In the ten initial roll-out sites which include Wessex Cancer Alliance (Southampton Care Commissioning Group) there are approximately 600,000 eligible patients, who between them will require a total of 200,000 CT scans.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 28/02/2019 11:51:35 answering member 4067 label Biography information for Steve Brine
tabling member	4478 label Biography information for Royston Smith